Opinion

Video

Capivasertib and Fulvestrant for Patients with Aromatase Inhibitor-resistant Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Results from the Phase III CAPItello-291 Trial

Author(s):

Hope S. Rugo, MD

Hope Rugo, MD reviews key data from the CAPItello-291 phase 3 trial recently presented at the San Antonio Breast Cancer Symposium in December 2022.

Related Videos
Adam M. Brufsky, MD, PhD, FACP
Sara M. Tolaney, MD, MPH
Chirag Shah, MD
Jason A. Mouabbi, MD
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Shipra Gandhi, MD
A panel of 5 experts on breast cancer
A panel of 5 experts on breast cancer
Management of Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoietin Stimulating Agent (ESA) Treatment
Related Content
Paolo Tarantino, MD, of Dana-Farber Cancer Institute
July 24th 2024

Pending Dato-DXd Approval Solidifies Importance of Sequencing in HR+ Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Lisa Conte
July 23rd 2024

Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Sonya Reid, MD, MPH
July 22nd 2024

Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer

Pedram Razavi, MD, PhD
July 22nd 2024

Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management